Key Figure. The nicotine metabolite ratio influences smoking
cessation outcomes on varenicline and the nicotine patch.
In smokers prospectively randomized to varenicline, nicotine patch, or placebo
based on the nicotine metabolite ratio or NMR, end-of-treatment quit rates and
odds ratios (OR) with 95% confidence intervals (CI) comparing the
efficacy of varenicline versus the nicotine patch as a function of NMR group
(faster vs. slower nicotine metabolizers) are shown in (a). There
was a significant NMR-by-treatment interaction on end-of-treatment quit rates:
ratio of odds ratios (ORR) = 1.89 (95% CI = 1.02, 3.45;
P=0.04) (a). In a longitudinal model including
end-of-treatment as well as 6-month and 12-month quit rates, the
NMR-by-treatment interaction was also significant: ORR = 1.96
(95% CI = 1.11, 3.46; P=0.02). Number needed to treat
analyses comparing the effectiveness of varenicline versus placebo, and nicotine
patch versus placebo, as a function of NMR group (faster vs. slower nicotine
metabolizers) are shown in (b). For example, 26 faster metabolizers
would need to be treated with the nicotine patch to have one smoker quit. The
full results from this clinical trial (NCT01314001) are found in a publication
by Lerman et al., 2015 [22]. Abbreviation: CI, confidence interval